应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
KYNB Kyntra Bio Inc
休市中 08-07 16:00:00 EDT
7.27
+0.29
+4.15%
盘后
7.27
+0.00
0.00%
19:20 EDT
最高
7.30
最低
6.97
成交量
5,200
今开
6.97
昨收
6.98
日振幅
4.73%
总市值
2,941万
流通市值
2,589万
总股本
404.54万
成交额
3.72万
换手率
0.15%
流通股本
356.12万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
Kyntra Bio发布罗沙司他新数据:无论环状铁粒幼细胞状态如何,均能改善低危MDS贫血患者输血独立性
美股速递 · 06-12
Kyntra Bio发布罗沙司他新数据:无论环状铁粒幼细胞状态如何,均能改善低危MDS贫血患者输血独立性
Kyntra Bio公布FG-3246联合恩杂鲁胺治疗转移性去势抵抗性前列腺癌的研究者发起1B/2期研究积极数据,将于2026年ASCO GU大会展示
美股速递 · 02-24
Kyntra Bio公布FG-3246联合恩杂鲁胺治疗转移性去势抵抗性前列腺癌的研究者发起1B/2期研究积极数据,将于2026年ASCO GU大会展示
加载更多
公司概况
公司名称:
Kyntra Bio Inc
所属市场:
NASDAQ
上市日期:
--
主营业务:
Kyntra Bio, Inc.于1993年在美国特拉华州注册成立。该公司是一家生物制药公司,专注于癌症生物学和贫血前沿领域的新疗法开发。该公司正在开发FG-3246,这是一种潜在的靶向CD46的first-in-class抗体药物偶联物,用于治疗转移性去势抵抗性前列腺癌和潜在的其他癌症。该计划还包括FG-3180的开发,这是一种相关的CD46靶向正电子发射断层扫描生物标志物和显像剂。
发行价格:
--
{"stockData":{"symbol":"KYNB","market":"US","secType":"STK","nameCN":"Kyntra Bio Inc","latestPrice":7.27,"timestamp":1786132800000,"preClose":6.9805,"halted":0,"volume":5200,"hourTrading":{"tag":"盘后","latestPrice":7.27,"preClose":7.27,"latestTime":"19:20 EDT","volume":12,"amount":87.03,"timestamp":1786144822978,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.04147267387722934,"floatShares":3561200,"shares":4045445,"eps":40.443214,"marketStatus":"休市中","change":0.2895,"latestTime":"08-07 16:00:00 EDT","open":6.97,"high":7.3,"low":6.97,"amount":37165,"amplitude":0.047275,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":40.443214,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1786348800000},"marketStatusCode":7,"adr":0,"listingDate":1415941200000,"exchange":"NASDAQ","adjPreClose":6.9805,"preHourTrading":{"tag":"盘前","latestPrice":7.25,"preClose":6.9805,"latestTime":"08:38 EDT","volume":198,"amount":1386.99,"timestamp":1786106315085,"change":0.2695,"changeRate":0.038608,"amplitude":0.038679},"postHourTrading":{"tag":"盘后","latestPrice":7.27,"preClose":7.27,"latestTime":"19:20 EDT","volume":12,"amount":87.03,"timestamp":1786144822978,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.9541536961226676},"requestUrl":"/m/hq/s/KYNB","defaultTab":"news","newsList":[{"id":"1192420942","title":"Kyntra Bio发布罗沙司他新数据:无论环状铁粒幼细胞状态如何,均能改善低危MDS贫血患者输血独立性","url":"https://stock-news.laohu8.com/highlight/detail?id=1192420942","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1192420942?lang=zh_cn&edition=full","pubTime":"2026-06-12 04:06","pubTimestamp":1781208416,"startTime":"0","endTime":"0","summary":"Kyntra Bio Inc公布了其药物罗沙司他的最新研究数据。数据显示,对于因低危骨髓增生异常综合征导致贫血的患者,无论其环状铁粒幼细胞状态如何,罗沙司他治疗均能显著改善患者的输血独立性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KYNB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173376495","title":"Kyntra Bio公布FG-3246联合恩杂鲁胺治疗转移性去势抵抗性前列腺癌的研究者发起1B/2期研究积极数据,将于2026年ASCO GU大会展示","url":"https://stock-news.laohu8.com/highlight/detail?id=1173376495","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1173376495?lang=zh_cn&edition=full","pubTime":"2026-02-24 06:11","pubTimestamp":1771884675,"startTime":"0","endTime":"0","summary":"Kyntra Bio公司宣布,其FG-3246与恩杂鲁胺联合用药方案针对转移性去势抵抗性前列腺癌患者的临床研究取得积极进展。这项由研究者发起的1B/2期试验数据显示出显著治疗潜力,相关完整数据报告已获选将于2026年美国临床肿瘤学会泌尿生殖系统肿瘤研讨会进行正式发布。\n该研究聚焦于晚期前列腺癌治疗领域的前沿探索,通过双药联用策略旨在突破现有治疗方案瓶颈。试验结果不仅验证了联合用药的安全性特征,更展现出令人鼓舞的疗效信号,为转移性去势抵抗性前列腺癌患者提供了新的治疗希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KYNB"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.kyntrabio.com","stockEarnings":[{"period":"1week","weight":0.0802},{"period":"1month","weight":-0.0294},{"period":"3month","weight":0.046},{"period":"6month","weight":-0.1156},{"period":"1year","weight":-0.0844},{"period":"ytd","weight":-0.172}],"compareEarnings":[{"period":"1week","weight":0.0351},{"period":"1month","weight":0.0374},{"period":"3month","weight":0.0483},{"period":"6month","weight":0.1197},{"period":"1year","weight":0.223},{"period":"ytd","weight":0.1339}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Kyntra Bio, Inc.于1993年在美国特拉华州注册成立。该公司是一家生物制药公司,专注于癌症生物学和贫血前沿领域的新疗法开发。该公司正在开发FG-3246,这是一种潜在的靶向CD46的first-in-class抗体药物偶联物,用于治疗转移性去势抵抗性前列腺癌和潜在的其他癌症。该计划还包括FG-3180的开发,这是一种相关的CD46靶向正电子发射断层扫描生物标志物和显像剂。","yearOnYearQuotes":[{"month":1,"riseRate":0.666667,"avgChangeRate":0.171748},{"month":2,"riseRate":0.333333,"avgChangeRate":-0.039992},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.057428},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.116567},{"month":5,"riseRate":0.416667,"avgChangeRate":-0.040314},{"month":6,"riseRate":0.666667,"avgChangeRate":0.006331},{"month":7,"riseRate":0.5,"avgChangeRate":-0.040858},{"month":8,"riseRate":0.416667,"avgChangeRate":0.017338},{"month":9,"riseRate":0.454545,"avgChangeRate":-0.009378},{"month":10,"riseRate":0.454545,"avgChangeRate":-0.070226},{"month":11,"riseRate":0.727273,"avgChangeRate":0.07854},{"month":12,"riseRate":0.636364,"avgChangeRate":0.096082}],"exchange":"NASDAQ","name":"Kyntra Bio Inc","nameEN":"Kyntra Bio Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Kyntra Bio Inc(KYNB)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Kyntra Bio Inc(KYNB)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Kyntra Bio Inc,KYNB,Kyntra Bio Inc股票,Kyntra Bio Inc股票老虎,Kyntra Bio Inc股票老虎国际,Kyntra Bio Inc行情,Kyntra Bio Inc股票行情,Kyntra Bio Inc股价,Kyntra Bio Inc股市,Kyntra Bio Inc股票价格,Kyntra Bio Inc股票交易,Kyntra Bio Inc股票购买,Kyntra Bio Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Kyntra Bio Inc(KYNB)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Kyntra Bio Inc(KYNB)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}